icon
icon
icon
icon
Upgrade
icon

BioNTech (BNTX.US) late-stage melanoma trial shows promising results

AInvestTuesday, Jul 30, 2024 9:30 pm ET
1min read

On July 30, BioNTech (BNTX.US) announced that the tumor mRNA vaccine BNT111+PD-1 achieved the primary endpoint of ORR in the treatment of advanced or metastatic melanoma patients who progressed after PD-1 treatment, and the results were significantly better than historical data. BioNTech and its partner Regeneron plan to present specific data at future medical meetings.

BioNTech has a wide range of tumor-related products, and tumor therapeutic vaccines are one of the key products. On the one hand, BioNTech has laid out personalized neoantigen mRNA vaccines (BNT122, mRNA-4157) like Moderna. On the other hand, BioNTech is actively developing fixed-antigen tumor mRNA vaccines, including HPV vaccine BNT113 and melanoma vaccine BNT111. In terms of clinical strategy, BioNTech's personalized neoantigen vaccines are mainly used for the adjuvant treatment of early tumors, to prevent postoperative recurrence, and fixed-antigen vaccines are used for the treatment of advanced tumors.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.